Back to Journals » Research and Reports in Biology » Volume 6

Hedgehog-Gli signaling in basal cell carcinoma and other skin cancers: prospects for therapy

Authors Pandolfi S, Stecca B

Received 3 December 2014

Accepted for publication 6 March 2015

Published 8 May 2015 Volume 2015:6 Pages 55—71

DOI https://doi.org/10.2147/RRB.S60262

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Professor Zvi Kelman


Silvia Pandolfi,1 Barbara Stecca1,2

1Laboratory of Tumor Cell Biology, Core Research Laboratory, Istituto Toscano Tumori, 2Department of Oncology, Azienda Ospedaliero- Universitaria Careggi, Florence, Italy

Abstract: The Hedgehog (Hh) signaling pathway is of critical importance during embryonic development, where it directs a number of cellular processes, including cell proliferation, differentiation, and patterning. In normal adult tissues, Hh signaling is mostly involved in stem cell maintenance, tissue repair, and regeneration. Over the last two decades, aberrant activation of Hh signaling has been linked to several types of cancer, including those of the skin. In particular, the critical role of Hh signaling in the development of basal cell carcinoma has been demonstrated by several mouse models and genetic mutation analyses. In addition, several clinical trials using Hh signaling inhibitors have been shown to be effective treatments in basal cell carcinoma. Recent evidence indicates that activation of the Hh pathway plays an important role in other types of human skin cancer, such as melanoma and cutaneous squamous cell carcinoma. In this review, we provide an overview of the roles of Hh pathway in skin cancers, including basal cell carcinoma, melanoma, and squamous cell carcinoma. Finally, we discuss the rapid development of drugs that target the Hh pathway and the implications for skin cancer therapy.

Keywords: Hedgehog, Gli transcription factors, basal cell carcinoma, melanoma, squamous cell carcinoma, small-molecule inhibitors
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]